Pharma News

Live Ebola virus can persist in the semen of some survivors for at least nine months, according to preliminary results of a study published on Wednesday.

[adsense:336x280:8701650588]

Researchers at the University of Cyprus have designed a micro-device that could help doctors detect cancers in the small intestine in the very early stages when cancerous cells cannot be easily detected, a university professor said on Wednesday.

A British study claiming that sitting down is no worse for your health than standing up.
The study also challenged advice from the UK National Health Service (NHS) based on other studies stating that "remaining seated for too long is bad for your health, regardless of how much exercise you do." The findings were published in the International Journal of Epidemiology.

Overuse of contraceptive pills by women can lead to increased blood coagulation, with an increased risk of cardiovascular problems, doctors have warned.

Scientists have now revealed that bowel cancer consists of four distinct diseases, each with its own set of biological characteristics. The study was published in Nature Medicine.

Bioengineers at the University of Illinois at Chicago developed a 'psychic robot' that knows what you really meant to do. The study is published online in PLOS ONE.

Researchers have now found that nitrate-rich beetroot juice helps the body acclimatize more quickly and thoroughly at high altitude. Mountain sickness caused by lower air pressures at high altitude which affect the ability of our bodies to take up oxygen. The study was published in Nitric Oxide: Biology and Chemistry.

Patients bore the brunt as nearly eight lakh pharmacy shops in the country were shut on 14th oct in a nationwide strike by the All India Organization of Chemists and Druggists (AIOCD) to protest against the online sale of drugs.

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

Incyte Corporation and Merck, known as MSD outside the United States and Canada, today announced the expansion of the companies’ ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incyte’s investigational selective IDO1 inhibitor, with Keytruda^® (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. The Phase 3 study, which is expected to begin in the first half of 2016, will be co-funded by Incyte and Merck.